# Alafair Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alafair-biosciences

- Industry: Medical Devices & Equipment
- Headquarters: Austin, US
- Website: www.alafairbiosciences.com
- Total disclosed funding: $2.5M
- Latest round: Series A (Aug 10, 2016)
- Investors on record: 3

## About

Alafair Biosciences, Inc. develops innovative medical devices that enhance postoperative recovery through advanced biopolymer technology. The company focuses on preventing surgical complications by offering plant-based solutions for soft tissue protection.Founded in 2011 and headquartered in Austin, US, Alafair Biosciences specializes in medical devices aimed at improving soft tissue recovery post-surgery. The company has completed a total of 7 deals, with the most recent being on April 18, 2019, when it raised USD 7.2 mn in SERIES B funding. The firm is led by founder John Joyoprayitno, who also serves as CEO, indicating continuity in leadership since inception.Alafair Biosciences specializes in medical devices designed to enhance postoperative soft tissue recovery through a patented platform technology utilizing natural biopolymers. The company's core offerings include plant-based devices aimed at protecting soft tissues such as tendons, peripheral nerves, ligaments, and skeletal muscles. These devices create a gliding surface between opposing tissues to prevent unwanted tethering, a common surgical complication. Primarily targeted at hand surgeons, orthopedic surgeons, and other specialists, Alafair's products are marketed across the United States.Alafair Biosciences generates revenue through direct sales of its medical devices to healthcare providers and institutions. Transactions predominantly occur in a business-to-business manner, with hospitals and surgical centers purchasing products for operational use. The company offers tailored pricing plans for bulk purchases and smaller clinics, with products under the VersaWrap brand being notable revenue contributors. Alafair emphasizes relationship-building with surgeons and healthcare facilities to ensure consistent availability and foster loyalty.As of April 2019, Alafair Biosciences plans to utilize the USD 7.2 mn raised in SERIES B funding to further develop its product offerings and expand into new markets. The company is focused on launching new products aimed at enhancing soft tissue recovery in the upcoming years, specifically targeting regions beyond the US to increase its market presence. These strategies underscore Alafair's commitment to advancing its medical device portfolio and reaching broader surgical applications.

## Funding rounds

- Series A, Aug 10, 2016, $2M — UT Horizon Fund, ATP Fund
- Series A, Sep 10, 2013, $0.5M — TEXO Ventures

## Investors

- TEXO Ventures (https://capitalatlas.ai/funds/texo-ventures) — Series A
- UT Horizon Fund (https://capitalatlas.ai/funds/ut-horizon-fund) — Series A
- ATP Fund (https://capitalatlas.ai/funds/atp-fund) — Series A